Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Neurology Market: Poised for Change and Innovation
- Novel Approaches to Neurological Disease Treatment
- Novel Targets
- Beta-Amyloid
- Beta-Secretase
- Tau Protein
- NMDA
- Nicotinic Receptors
- HMG-CoA Reductase
- Novel Technologies
- Stem Cell Therapy
- Deep-Brain Stimulation
- Company Profi les
- Lundbeck
- CoMentis
- Targacept
- Vitae Pharmaceuticals
- Outlook
Tables
- 1. Descriptions of Select Neurological Diseases
- 2. Top-Selling Products for the Treatment of Neurological Diseases, 2008
- 3. Beta-Amyloid Agents in Clinical Development for the Treatment of
Neurological Diseases
- 4. Beta-Secretase Agents in Clinical Development for the Treatment of
Neurological Diseases
- 5. Tau Protein Agents in Clinical Development for the Treatment of
Neurological Diseases
- 6. NMDA Agents in Clinical Development for the Treatment of Neurological
Diseases
- 7. Nicotinic Receptor Agents in Clinical Development for the Treatment of
Neurological Diseases
- 8. Benefi ts and Drawbacks of Stem Cell Types in the Treatment of
Neurological Diseases
- 9. Select Companies Developing Stem Cell Therapies
- 10. Select Deals Focusing on the Development of Neurological Disease
Treatments
Figures
- 1. Worldwide Neurology Market Growth, 2004-2008
- 2. Areas of the Brain Targeted by Deep Brain Stimulation
|
Related Report
|
View Cart
